EQT

Perfuze is a neurovascular medical device company based in Galway, Ireland, established in 2018. The company specializes in developing innovative catheter technology aimed at treating acute ischemic stroke. By utilizing its proprietary catheter-based aspiration platform, Perfuze focuses on optimizing the efficiency of clot removal, which in turn seeks to enhance clinical outcomes and reduce procedural times. This technology aims to simplify the treatment process while minimizing the need for alternative interventions, providing patients with a cost-effective solution for ischemic stroke therapy.

Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases. Tauopathies are currently untreatable neurodegenerative diseases that rapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.

Vico Therapeutics B.V., founded in 2019 and based in Leiden, the Netherlands, specializes in developing RNA modulating therapies aimed at treating rare neurological disorders. The company's primary focus is on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome. By discovering and delivering innovative therapies, Vico Therapeutics aims to address the unmet medical needs of patients suffering from these severe central nervous system disorders, thereby enhancing treatment options available to medical professionals.

Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly transformative antibody-drug conjugates (ADCs). The company focuses on creating innovative chemotherapeutic medications that are specifically tailored to combat cancer and chronic disorders. By integrating proprietary technologies with disease-specific biology, Tubulis aims to identify novel protein-drug combinations that enable clinicians to treat cancer patients while minimizing the risks and side effects typically associated with traditional chemotherapy.

Phagenesis is developing a device for the treatment for dysphagia, the inability to swallow safely, that often accompanies stroke or other neuro-deficit diseases. The approach is to harness the brain's own capacity for relearning functions that have been lost through brain damage (via "neuroplasticity" or "cortical remapping"). Focusing initially on the care of stroke patients as they recover in hospital (acute care), Prof Shaheen Hamdy of the University of Manchester, UK, painstakingly devised a method of delivering electrical signals from the pharynx (throat) along nerve cells directly to the relevant parts of the brain. The results of his work have been published in top peer-reviewed scientific and medical journals, including The Lancet, the Nature group of publications, and Gastroenterology.

Vico Therapeutics B.V., founded in 2019 and based in Leiden, the Netherlands, specializes in developing RNA modulating therapies aimed at treating rare neurological disorders. The company's primary focus is on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome. By discovering and delivering innovative therapies, Vico Therapeutics aims to address the unmet medical needs of patients suffering from these severe central nervous system disorders, thereby enhancing treatment options available to medical professionals.

LUMA Vision is a company focused on developing connected intra-vascular medical devices to enhance the treatment of cardiac arrhythmias. By leveraging advanced four-dimensional imaging and artificial intelligence, LUMA Vision aims to transform electrophysiology and structural heart interventions. Their technology facilitates real-time tissue analysis, enabling healthcare professionals to perform cardiac procedures more effectively. This innovation is designed to improve patient outcomes, enhance procedural safety, and ultimately lower costs within the healthcare system.

Shinobi Therapeutics specializes in the development of cell therapies that leverage hypoimmune CD8αβ iPS-T cells to interact with the immune system for the treatment of cancer and various genetic diseases. The company's innovative approach incorporates advanced immune evasion technology to enhance the effectiveness and accessibility of these therapies. By focusing on durable responses and the potential for redosing, Shinobi aims to reduce costs and improve patient outcomes in the healthcare sector.

Nouscom is a biotechnology company focused on developing an immunotherapy platform that creates modified viral vector vaccines for cancer treatment. The company utilizes a range of engineered viral vectors optimized for the effective expression of long strings of tumor neoantigens. Additionally, its platform includes tools designed to induce broad and potent antitumor T-cell responses, which aim to enhance cancer-specific cellular immunity in patients.

AgomAb Therapeutics N.V., based in Gent, Belgium, focuses on developing innovative therapies using anti-MET antibodies for treating various diseases. The company specializes in creating agonistic monoclonal antibodies, known as agomAbs, which aim to stimulate molecular and cellular repair mechanisms to regenerate damaged tissues. This approach has the potential to restore organ function in patients suffering from fibrotic, inflammatory, autoimmune, and degenerative conditions. AgomAb is committed to exploring biologically validated pathways, particularly Transforming Growth Factor β and Hepatocyte Growth Factor, and is equipped with expertise in organ-specific small molecules and high-affinity antibodies. With a diversified clinical pipeline targeting multiple fibrotic conditions and comprehensive research and development capabilities, AgomAb Therapeutics is well-positioned in the therapeutic landscape.

Minervax is focused on developing a vaccine to prevent infections caused by Group B streptococcus (GBS), which can lead to serious health issues in newborns and adverse pregnancy outcomes. The company is researching a specific fusion protein that has demonstrated the ability to stimulate strong protective immunity against various clinically significant GBS strains. By utilizing this innovative approach, Minervax aims to provide medical professionals with an effective tool to protect newborns from potentially life-threatening bacterial infections associated with GBS.

Evommune, Inc. is a biotechnology company based in Los Altos, California, that focuses on developing and manufacturing tissue-based medicines aimed at treating inflammatory diseases. Founded in 2020, the company employs a proprietary tissue-based platform to accelerate the discovery of novel therapies, with a particular emphasis on immunology and dermatology. Evommune's approach seeks not only to alleviate the symptoms of inflammatory disorders but also to halt disease progression, thereby improving the quality of life for patients. Its pipeline includes initiatives targeting prevalent inflammatory conditions, with a commitment to advancing patient care by creating best-in-class treatment options. Through innovative strategies, Evommune aims to drive meaningful advancements in the field of inflammatory disease management.

FundamentalVR have been working with leading pharmaceutical companies to combine virtual and mixed reality with haptic feedback using their ‘FeelRealVR’ platform to create simulated surgical procedures to help educate and train healthcare professionals. The company works at the nexus of haptics, machine learning, and immersive technologies (XR). FundamentalVR was established in 2012 by Chris Scattergood in London, England.

Xilis, Inc. is a biotechnology company based in Chapel Hill, North Carolina, founded in 2019. It specializes in developing advanced organoid technologies aimed at guiding precision therapy for cancer patients and enhancing drug discovery processes. The company's flagship platform, XilisµO, facilitates rapid diagnostics and personalized drug screening while providing scalable, patient-derived models for high-throughput drug discovery. This technology supports physicians and pharmaceutical companies in creating tailored treatments by enabling effective drug screening, ultimately contributing to more precise and cost-efficient cancer therapies.

ImCheck Therapeutics is a developer of immuno-modulatory antibodies designed for the treatment of cancer and other immune-related diseases. The company's services are engaged in the discovery and development of immunomodulators for treating breast cancer, gastric, ovarian cancer cells and other solid solid tumours.

Ariceum Therapeutics is a privately held radiopharmaceutical firm in the clinical stage that specializes in the detection and targeted treatment of aggressive malignancies, such as neuroendocrine and other hard-to-treat cancers. 177Lu-satoreotide tetraxetan (Satoreotide), the company's primary targeted systemic radiopharmaceutical therapy, is an antagonist of the somatostatin type 2 receptor (SSTR2), which is overexpressed in many neuroendocrine tumors. For the simultaneous diagnosis and targeted radionuclide treatment of neuroendocrine malignancies, some aggressive tumors, and childhood cancer, which currently offers few treatment choices and a poor prognosis, we are developing satoreotide as a "theranostic" pair.

Perfuze is a neurovascular medical device company based in Galway, Ireland, established in 2018. The company specializes in developing innovative catheter technology aimed at treating acute ischemic stroke. By utilizing its proprietary catheter-based aspiration platform, Perfuze focuses on optimizing the efficiency of clot removal, which in turn seeks to enhance clinical outcomes and reduce procedural times. This technology aims to simplify the treatment process while minimizing the need for alternative interventions, providing patients with a cost-effective solution for ischemic stroke therapy.

3Shape is a leading provider of digital dentistry solutions, specializing in intra-oral scanning, lab scanning, and cone-beam computed tomography (CT) scanners. The company develops advanced software for computer-aided design (CAD) and computer-aided manufacturing (CAM) that supports dentists and dental laboratories in over 100 countries. By offering state-of-the-art scanning technology and software tools, 3Shape enhances the capabilities of dental and hearing professionals, enabling them to deliver more effective treatment and superior patient care.

AviadoBio is focused on developing innovative gene therapies aimed at transforming the lives of individuals affected by neurodegenerative disorders, specifically frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company leverages advanced research from King's College London and the UK Dementia Research Institute to create its therapeutic platform. By integrating a comprehensive understanding of brain biology with proprietary gene therapy techniques, AviadoBio seeks to address the challenges of effectively delivering treatments to targeted areas in the brain. This approach aims to enhance the therapeutic potential of gene therapies, offering hope for halting or potentially reversing the progression of these debilitating diseases.

Icon Group is a global provider of cancer care services, focusing on delivering comprehensive care to patients at accessible locations. The company offers a range of services including medical and radiation oncology, hematology, health screening, pharmacy, chemotherapy, and compounding. By aiming to enhance the quality of care available, Icon Group ensures that patients receive tailored treatment options close to their homes, thereby improving the overall patient experience in cancer care.

DNA Script is a pioneering company in the field of DNA synthesis, focused on enhancing life science and human health through innovative technology. The company has developed a unique enzymatic process that allows for the production of synthetic DNA using natural enzymes. This technology underpins their benchtop DNA printer, SYNTAX, which enables laboratories to synthesize their own oligonucleotides. By doing so, DNA Script provides researchers with greater control over their workflows, facilitating faster access to essential genomic materials for various applications in molecular biology and genomics. This capability accelerates experimentation and supports the development of new therapeutics, positioning DNA Script as a key player in the biotechnology sector.

Egle Therapeutics SAS is a biotechnology company based in Paris, France, founded in 2020. It specializes in developing innovative immunotherapies that target immune suppressor regulatory T-cells (Tregs) for the treatment of oncology and autoimmune diseases. The company's research focuses on a proprietary drug pipeline that includes computationally designed IL-2 variants aimed at modulating Treg activity. This approach seeks to either engage or dis-engage Tregs, facilitating the development of therapies that can effectively combat cancer and other related conditions by addressing the immune suppression caused by Tregs. Egle Therapeutics aims to advance its unique portfolio to provide new treatment options in the healthcare field.

LUMA Vision is a company focused on developing connected intra-vascular medical devices to enhance the treatment of cardiac arrhythmias. By leveraging advanced four-dimensional imaging and artificial intelligence, LUMA Vision aims to transform electrophysiology and structural heart interventions. Their technology facilitates real-time tissue analysis, enabling healthcare professionals to perform cardiac procedures more effectively. This innovation is designed to improve patient outcomes, enhance procedural safety, and ultimately lower costs within the healthcare system.

Visus Therapeutics is a clinical-stage company developing innovative medicines to improve the vision for people around the world.

The blikk group is a growing network of radiological, nuclear medicine and nephrology practices using dialysis. As a reliable partner for patients and referring physicians, the practices of the association make a significant contribution to high-quality medical care. They all share the common claim to the highest quality and excellent education and training of medical and non-medical staff in all disciplines.

Xilis, Inc. is a biotechnology company based in Chapel Hill, North Carolina, founded in 2019. It specializes in developing advanced organoid technologies aimed at guiding precision therapy for cancer patients and enhancing drug discovery processes. The company's flagship platform, XilisµO, facilitates rapid diagnostics and personalized drug screening while providing scalable, patient-derived models for high-throughput drug discovery. This technology supports physicians and pharmaceutical companies in creating tailored treatments by enabling effective drug screening, ultimately contributing to more precise and cost-efficient cancer therapies.

PAREXEL International Corporation, a biopharmaceutical services company, provides clinical research, medical communications, consulting, commercialization, and advanced technology products and services to the pharmaceutical, biotechnology, and medical device industries worldwide. The company operates in three segments: Clinical Research Services (CRS), PAREXEL Consulting and Medical Communications Services (PCMS), and Perceptive Informatics (Perceptive). The CRS segment offers clinical trials management, observational studies, patient/disease registries and post-marketing surveillance, data management and biostatistics, epidemiology and health economics/outcomes research, clinical logistics, pharmacovigilance, and clinical pharmacology, as well as related medical affairs, patient recruitment, and investigator site services. This segment manages various aspects of clinical trials, including study and protocol design, case report form design, paper or electronic questionnaires design, patient enrollment, study monitoring and data collection, data analysis, report writing, and medical services. The PCMS segment provides technical expertise and advice in various areas, such as drug development, regulatory affairs, product pricing and reimbursement, and good manufacturing practice compliance consulting; and market development, product development, and targeted communications services in support of product launch. Its consultants also identify alternatives and propose solutions to address clients’ product development, registration, and commercialization issues. In addition, this segment provides reimbursement and market access services. The Perceptive segment provides information technology solutions comprising medical imaging and systems integration services; ClinPhone RTSM, CTMS, and DataLabs EDC products; Web-based portals; and patient diary applications. The company was founded in 1983 and is headquartered in Waltham, Massachusetts.

Cerba HealthCare S.A.S., is a clinical pathology laboratory, provides routine and specialized clinical laboratory testing services.

XyloCor Therapeutics, based in Newtown Square, Pennsylvania, is a biopharmaceutical company dedicated to developing gene therapies for the treatment of cardiovascular diseases, particularly advanced coronary artery disease. Its lead product candidate, XC001, is currently in clinical development for patients suffering from refractory angina, addressing critical unmet medical needs for those who have exhausted conventional treatment options. Additionally, the company is developing XC002, aimed at regenerating cardiac tissue in patients with compromised heart function due to previous heart attacks and resultant heart failure. XyloCor's innovative gene therapy technologies focus on stimulating the formation of new coronary blood vessels, thereby improving blood supply to areas of the heart that are insufficiently perfused. The company collaborates with Weill Cornell Medical College to enhance its therapeutic approaches and outcomes for patients.

Vico Therapeutics B.V., founded in 2019 and based in Leiden, the Netherlands, specializes in developing RNA modulating therapies aimed at treating rare neurological disorders. The company's primary focus is on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome. By discovering and delivering innovative therapies, Vico Therapeutics aims to address the unmet medical needs of patients suffering from these severe central nervous system disorders, thereby enhancing treatment options available to medical professionals.

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. Cybin’s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The Company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder, and has a research pipeline of investigational psychedelic-based compounds. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands, and Ireland. For company updates and to learn more about Cybin, visit www.cybin.com or follow the team on Twitter, LinkedIn, YouTube, and Instagram.

LUMA Vision is a company focused on developing connected intra-vascular medical devices to enhance the treatment of cardiac arrhythmias. By leveraging advanced four-dimensional imaging and artificial intelligence, LUMA Vision aims to transform electrophysiology and structural heart interventions. Their technology facilitates real-time tissue analysis, enabling healthcare professionals to perform cardiac procedures more effectively. This innovation is designed to improve patient outcomes, enhance procedural safety, and ultimately lower costs within the healthcare system.

Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solutions to patients suffering from CNS disorders.

Kiadis Pharma N.V. is a biopharmaceutical company based in Amsterdam, the Netherlands, specializing in cell-based immunotherapy products aimed at treating blood cancers and inherited blood disorders. The company is currently advancing K-NK002, which is undergoing Phase II clinical trials for blood cancer patients receiving haploidentical hematopoietic stem cell transplants with the post-transplant cyclophosphamide protocol. Additionally, Kiadis Pharma is developing K-NK003, currently in Phase I/II trials for patients with acute myeloid leukemia relapse or refractory cases. The preclinical product pipeline includes K-NK00X, a natural killer (NK) cell therapy candidate targeting various solid tumors. Kiadis Pharma also collaborates with several institutions, including Harbour BioMed and Erasmus Medical Center, to explore a combination of monoclonal antibodies and natural killer cells as a potential treatment for COVID-19. Founded in 1997, Kiadis Pharma is committed to addressing significant unmet medical needs in the treatment of blood-related conditions.

Schülke & Mayr GmbH manufactures and supplies disinfectants, antiseptics, preservatives, biocides, medical skin care products, an active substance for deodorants, and system cleaners.

Health Management International Ltd is a regional private healthcare provider operating in Singapore, Malaysia, and Indonesia. The company owns two tertiary hospitals in Malaysia and a healthcare training center in Singapore, along with a network of representative offices across the three countries. It specializes in delivering a range of medical services, including cardio-vascular care, digestive health, minimally invasive surgeries, and diagnostic services. By focusing on both local and international patients, Health Management International aims to enhance the accessibility and quality of healthcare in the region.

ImCheck Therapeutics is a developer of immuno-modulatory antibodies designed for the treatment of cancer and other immune-related diseases. The company's services are engaged in the discovery and development of immunomodulators for treating breast cancer, gastric, ovarian cancer cells and other solid solid tumours.

Galderma is a global company founded in 1981, specializing in innovative medical solutions for dermatological needs. With a presence in 80 countries and a workforce of approximately 5,500 employees, Galderma offers a diverse product portfolio that addresses various skin conditions, including acne, rosacea, psoriasis, and skin cancer. The company is known for its strategic brands, such as Epiduo®, Differin®, and Restylane®, which cater to both therapeutic and aesthetic dermatology. Originally established as a joint venture between Nestlé and L'Oréal, Galderma became a standalone entity in 2019 after being acquired by a consortium led by EQT. The company focuses on delivering science-based skincare solutions and actively serves healthcare professionals worldwide.

Pharvaris is a clinical-stage company dedicated to the discovery and development of therapies for rare diseases, particularly focusing on hereditary angioedema (HAE) and other conditions mediated by bradykinin. The company is advancing an oral bradykinin B2 receptor antagonist, with its lead candidate, PHA121, currently undergoing Phase 1 clinical trials. Pharvaris aims to provide new treatment options that offer alternatives to injected therapies for all sub-types of HAE. The company was co-founded by key individuals involved in the development of icatibant, a previously established treatment for HAE, ensuring a strong foundation in this therapeutic area.

Ellab is a manufacturer specializing in thermal validation and monitoring products, providing solutions that measure, record, and validate critical parameters in thermal processing. The company offers a diverse range of high-precision and modular systems, including wireless data loggers and thermocouple-based instruments, designed to support various applications such as sterilization, freeze-drying, environmental chambers, heat tunnels, and pasteurization. With a global presence, Ellab sells its products in over 65 countries, focusing on reducing the time-to-market and minimizing the risk of product loss for its clients.

Waystar simplifies and unifies the healthcare revenue cycle with innovative technology that allows clients to collect more with less cost and less stress, so they can focus on their goals, patients, and communities. Waystar has scored Best in KLAS® claims clearinghouse every year since 2010, including 2018, and earned multiple #1 rankings in both medical claims processing and patient payment solutions from Black Book™ surveys since 2012. The Waystar platform supports more than 400,000 providers, hospitals, health systems and ambulatory services organizations and partners with the leading EHR and practice management solution providers.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

DNA Script is a pioneering company in the field of DNA synthesis, focused on enhancing life science and human health through innovative technology. The company has developed a unique enzymatic process that allows for the production of synthetic DNA using natural enzymes. This technology underpins their benchtop DNA printer, SYNTAX, which enables laboratories to synthesize their own oligonucleotides. By doing so, DNA Script provides researchers with greater control over their workflows, facilitating faster access to essential genomic materials for various applications in molecular biology and genomics. This capability accelerates experimentation and supports the development of new therapeutics, positioning DNA Script as a key player in the biotechnology sector.

MHC Asia is a managed healthcare provider based in Singapore, serving over 800,000 corporate employees through more than 1,200 clinical care touchpoints. The company focuses on delivering corporate wellness programs and improving workplace well-being by collaborating with various organizations, including multinational corporations and small to medium-sized enterprises. Appointed as the Program Manager by the Health Promotion Board in 2020, MHC implements health and wellness initiatives across the corporate sector. The company emphasizes the quality of wellness providers through a rigorous approval process and oversees the administration of HPB grants for wellness programs. MHC also operates a healthcare technology platform that aggregates health, wellness, and lifestyle data, providing organizations with actionable insights to tailor their health offerings. This approach aims to enhance the quality of life for employees while optimizing the balance between cost and care quality. Additionally, MHC has successfully implemented chronic management programs that have resulted in savings exceeding 20% for its clients.

Igenomix offers genetic testing services tailored for reproductive health patients and clinics. The company focuses on various aspects of reproductive genetics, including non-invasive prenatal testing (NACE), carrier genetic testing (CGT), preimplantation genetic diagnosis (PGD), and endometrial receptivity analysis (ERA). Additionally, Igenomix engages in genomic studies related to embryonic viability and endometrial receptivity, aiming to address factors contributing to infertility. By providing these specialized services, Igenomix supports couples seeking to conceive and enhances the capabilities of reproductive medicine practitioners.

Snipr Biome ApS is a biotechnology company based in Copenhagen, Denmark, focusing on the development of CRISPR technology for the treatment of microbial diseases. Established in 2017, the company aims to revolutionize how such diseases are addressed by leveraging the adaptive immune system to create medicines that selectively target and eliminate harmful bacteria based on their specific DNA sequences. By utilizing a novel approach that subverts elements of the endogenous bacterial CRISPR machinery, Snipr Biome provides health professionals with innovative tools for targeted microbiome engineering, enhancing the precision and effectiveness of treatments for bacterial infections.

Arvelle Therapeutics is a biopharmaceutical company with the mission of bringing innovative solutions to patients suffering from CNS disorders.

XyloCor Therapeutics, based in Newtown Square, Pennsylvania, is a biopharmaceutical company dedicated to developing gene therapies for the treatment of cardiovascular diseases, particularly advanced coronary artery disease. Its lead product candidate, XC001, is currently in clinical development for patients suffering from refractory angina, addressing critical unmet medical needs for those who have exhausted conventional treatment options. Additionally, the company is developing XC002, aimed at regenerating cardiac tissue in patients with compromised heart function due to previous heart attacks and resultant heart failure. XyloCor's innovative gene therapy technologies focus on stimulating the formation of new coronary blood vessels, thereby improving blood supply to areas of the heart that are insufficiently perfused. The company collaborates with Weill Cornell Medical College to enhance its therapeutic approaches and outcomes for patients.

HyTest Ltd. is a manufacturer of monoclonal antibodies and antigens, primarily serving the In Vitro Diagnostic (IVD) industry. Established in 1994 and located in Turku, Finland, the company specializes in developing products for various clinical areas, including cardiac markers, infectious diseases, and metabolic syndrome, as well as veterinary diagnostics. HyTest offers innovative solutions for assay development and research applications, providing a range of products such as antibodies, antigens, and biomarkers. By focusing on research and development, HyTest enables its clients to deliver accurate testing solutions across diverse healthcare sectors.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2015, the company is dedicated to creating first-in-class therapies aimed at selectively killing cancer cells. Artios's product pipeline features several promising programs, including a focus on DNA polymerase theta (Polθ), which plays a crucial role in DNA repair processes. Additionally, the company is advancing an in-licensed program that targets a newly identified protein linked to DDR and is developing a novel treatment aimed at DNA nucleases involved in these pathways. Artios collaborates with Cancer Research Technology and prominent DNA repair researchers globally to enhance its research and development efforts.

Biovian is a contract manufacturing organization specializing in the biopharmaceutical sector, offering comprehensive services from early development to the production of finished vials. Established in 2003, Biovian operates a 2700 m² facility that is certified by the European Medicines Agency and inspected by the FDA for current Good Manufacturing Practice (cGMP) production. The company focuses on providing drug development and manufacturing services tailored for small and medium-sized biotechnology firms, supporting the development of innovative gene therapies and biopharmaceuticals. With extensive experience in biopharmaceutical process development and quality assurance, Biovian positions itself as a reliable partner for clients seeking to bring their products to market.

Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.The company's technology uses Vofatamab, a human monoclonal antibody that targets and specifically blocks the activity of FGFR3 (fibroblast growth factor receptor 3), enabling medical practitioners to treat patients with early stage and metastatic bladder cancer effectively.

Merus B.V. is a clinical-stage biomedical company focused on the discovery and development of antibody-based biopharmaceuticals, specifically in the field of immuno-oncology. The company utilizes its proprietary Oligoclonics technology to produce a class of human antibodies, which allows for the creation of a mixture of therapeutic antibodies targeting a common antigen from a single cell clone. Additionally, Merus develops bispecific antibody therapeutics known as Biclonics, which are designed to engage multiple targets simultaneously. The company's pipeline includes several product candidates such as MCLA-128, MCLA-117, and MCLA-158, among others, all aimed at addressing various cancer indications.

Simplify Medical, Inc. is a medical device company that specializes in the design, development, manufacturing, and marketing of cervical and lumbar artificial discs for spinal use. Notably, it offers the Simplify Disc, a non-metallic cervical artificial disc that is MRI-compatible, allowing for comprehensive diagnostic imaging while eliminating the need for CT scans. This product addresses single-level symptomatic cervical disc disease and is aimed at skeletally mature patients requiring reconstruction following discectomy. Founded in 2013 and based in Sunnyvale, California, the company markets its products through distributors in various international markets, including the United Kingdom and Germany. Simplify Medical is committed to minimizing patient exposure to radiation and preserving the natural range of motion in the spine with its innovative artificial disc technology.

Simplify Medical, Inc. is a medical device company that specializes in the design, development, manufacturing, and marketing of cervical and lumbar artificial discs for spinal use. Notably, it offers the Simplify Disc, a non-metallic cervical artificial disc that is MRI-compatible, allowing for comprehensive diagnostic imaging while eliminating the need for CT scans. This product addresses single-level symptomatic cervical disc disease and is aimed at skeletally mature patients requiring reconstruction following discectomy. Founded in 2013 and based in Sunnyvale, California, the company markets its products through distributors in various international markets, including the United Kingdom and Germany. Simplify Medical is committed to minimizing patient exposure to radiation and preserving the natural range of motion in the spine with its innovative artificial disc technology.

ImCheck Therapeutics is a developer of immuno-modulatory antibodies designed for the treatment of cancer and other immune-related diseases. The company's services are engaged in the discovery and development of immunomodulators for treating breast cancer, gastric, ovarian cancer cells and other solid solid tumours.

Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.The company's technology uses Vofatamab, a human monoclonal antibody that targets and specifically blocks the activity of FGFR3 (fibroblast growth factor receptor 3), enabling medical practitioners to treat patients with early stage and metastatic bladder cancer effectively.

OxThera AB is a biopharmaceutical company focused on developing treatments for primary and secondary hyperoxaluria, a condition that can lead to kidney stones and impaired kidney function. Founded in 2005 and based in Stockholm, Sweden, with an additional location in Knoxville, Tennessee, OxThera manufactures two main products: Oxabact and Oxazyme. Oxabact is an orally administered composition of live bacteria designed to enhance the removal of oxalate produced by the body, while Oxazyme is a non-systemic oral drug that contains recombinant oxalate decarboxylase, aimed at treating dietary hyperoxaluria and preventing kidney stones. The company holds worldwide patents for its innovative therapies and has received Orphan Drug designations for Oxabact in both Europe and the United States. Through its advanced biotherapy technologies, OxThera aims to improve kidney health and preserve organ function in patients affected by hyperoxaluria.

Immunic Therapeutics is a clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies for chronic inflammatory and autoimmune diseases. The company has a pipeline that includes three small molecule products. Its lead program, IMU-838, is a selective immune modulator that works by inhibiting the enzyme DHODH, targeting conditions such as multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. The second product, IMU-935, functions as an inverse agonist of the transcription factor RORγt and is being developed for psoriasis, castration-resistant prostate cancer, and Guillain-Barré syndrome. Lastly, IMU-856 aims to restore intestinal barrier function and is intended for diseases associated with bowel barrier dysfunction. Through these innovative therapies, Immunic Therapeutics aims to address significant unmet medical needs in the field of immunology.

Vivasure Medical Limited is a medical device company based in Galway, Ireland, specializing in the research, development, and manufacture of arterial and venous closure devices utilizing its patented PerQseal technology. The company focuses on creating polymer implants and delivery systems aimed at minimally invasive vessel closures in the fields of cardiology, interventional radiology, and vascular surgery. Its primary product is a large-bore percutaneous closure device that employs an absorbable patch to effectively close large arteriotomies following transcatheter procedures, including transcatheter aortic valve replacement and endovascular aneurysm repair. Established in 2008, Vivasure Medical is dedicated to advancing medical solutions that enhance patient outcomes in vascular access procedures.

Rotation Medical Inc. is a medical device company based in Plymouth, Minnesota, specializing in the development of a minimally invasive rotator cuff implant system designed for the treatment of rotator cuff diseases. The company's primary product is a collagen scaffold that is affixed to the affected rotator cuff tendon, aimed at managing tendon injuries and providing protection for both small and larger rotator cuff tears. Founded in 2009 and initially known as Denali Medical Inc., the company rebranded to Rotation Medical in March 2010. As of December 2017, Rotation Medical operates as a subsidiary of Smith & Nephew plc.

Press Ganey partners with more than 10,000 health care organizations worldwide to create and sustain high performing organizations, and, ultimately, improve the overall health care experience. The company offers a comprehensive portfolio of solutions to help clients operate efficiently, improve quality, increase market share and optimize reimbursement. Press Ganey works with clients from across the continuum of care – hospitals, medical practices, home care agencies and other providers – including 50 percent of all U.S. hospitals.

Nouscom is a biotechnology company focused on developing an immunotherapy platform that creates modified viral vector vaccines for cancer treatment. The company utilizes a range of engineered viral vectors optimized for the effective expression of long strings of tumor neoantigens. Additionally, its platform includes tools designed to induce broad and potent antitumor T-cell responses, which aim to enhance cancer-specific cellular immunity in patients.

Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.The company's technology uses Vofatamab, a human monoclonal antibody that targets and specifically blocks the activity of FGFR3 (fibroblast growth factor receptor 3), enabling medical practitioners to treat patients with early stage and metastatic bladder cancer effectively.

Lima Corporate is the Italian multinational in orthopaedics and traumatology. Lima Corporate is a maker of orthopedic equipment for doctors and healthcare practitioners. The company provides a variety of orthopedics and traumatology surgical equipment and devices, as well as implantable prostheses for knee, hip, shoulder, and minor joint arthroplasty, allowing clients to receive customised hardware that promotes patient-centered treatment.

Luxendo specializes in the development and manufacture of advanced light-sheet fluorescence microscopy instruments, specifically Single Plane Illumination Microscopes (SPIM). Originally developed at the European Molecular Biology Laboratory by Lars Hufnagel and his team, the SPIM technology offers a novel approach to bio-imaging by combining optical sectioning with multiple-view imaging. This technique allows for rapid three-dimensional imaging of living specimens, such as spheroids and whole organisms, without the need for sample rotation. The design prioritizes gentle handling, making it suitable for delicate cell cultures and developing embryonic samples. As a result, Luxendo's instruments enable scientists to observe living organisms over extended periods without causing photo damage, thereby enhancing research capabilities in various biological fields.

Neuravi Limited, founded in 2009 and headquartered in Galway, Ireland, specializes in the design and development of innovative clot retrieval devices aimed at restoring blood flow in patients experiencing ischemic strokes caused by arterial blockages in the brain. The company's primary product, the EmboTrap revascularization device, is utilized in the treatment of acute ischemic strokes and is available in several European countries, including Belgium, Denmark, France, Germany, and Spain. Neuravi's focus on neuro-interventional therapies is backed by extensive research into the mechanisms of stroke, particularly regarding the capture and removal of clots, which enhances treatment efficacy and improves patient outcomes. The company collaborates with international researchers and clinicians to foster the development of new solutions for this critical medical challenge. As of April 2017, Neuravi operates as a subsidiary of DePuy Ireland Unlimited Company.

Merus B.V. is a clinical-stage biomedical company focused on the discovery and development of antibody-based biopharmaceuticals, specifically in the field of immuno-oncology. The company utilizes its proprietary Oligoclonics technology to produce a class of human antibodies, which allows for the creation of a mixture of therapeutic antibodies targeting a common antigen from a single cell clone. Additionally, Merus develops bispecific antibody therapeutics known as Biclonics, which are designed to engage multiple targets simultaneously. The company's pipeline includes several product candidates such as MCLA-128, MCLA-117, and MCLA-158, among others, all aimed at addressing various cancer indications.

Affimed NV is a clinical-stage biopharmaceutical company focused on developing targeted cancer immunotherapies. With nearly two decades of expertise in the innate immune system, Affimed aims to provide innovative solutions to enhance cancer treatment outcomes. The company is engaged in the discovery, pre-clinical, and clinical development of antibodies that leverage innate cell engager-based medicines, addressing the limitations of existing immuno-oncology therapies. In addition to its product development efforts, Affimed also generates revenue by offering research and development services to third parties, utilizing both its own and third-party intellectual property.

Rotation Medical Inc. is a medical device company based in Plymouth, Minnesota, specializing in the development of a minimally invasive rotator cuff implant system designed for the treatment of rotator cuff diseases. The company's primary product is a collagen scaffold that is affixed to the affected rotator cuff tendon, aimed at managing tendon injuries and providing protection for both small and larger rotator cuff tears. Founded in 2009 and initially known as Denali Medical Inc., the company rebranded to Rotation Medical in March 2010. As of December 2017, Rotation Medical operates as a subsidiary of Smith & Nephew plc.

Heart Metabolics Limited is pioneering a pharmaceutical therapy for the treatment of hypertrophic cardiomyopathy (“HCM”). HCM is a condition in which the heart muscle becomes thick. The thickening makes it harder for blood to leave the heart forcing the heart to work harder to pump blood, leading in many cases to heart failure. Sudden death is caused frequently. There are over 100,000 cases of HCM in the United States alone, often presenting more severely in young adults and athletes; unfortunately the younger the individual is when diagnosed with HCM, the more likely that the individual has a severe form. Although various cardiovascular drugs are currently used to treat HCM, there are patients who are not being helped by current therapeutics. In response to this medical need and based on encouraging phase II clinical trial results to date, Heart Metabolics is developing perhexiline as a therapeutic for all types of HCM. Perhexiline is currently an approved drug in Australia and New Zealand for the treatment of angina. Heart Metabolics plans to conduct clinical trials in the U.S. and seek FDA approval of perhexiline as an orphan drug; the company currently has such an orphan designation from the FDA.

The I-MED Network is Australia’s largest private medical imaging network, with clinics in all major metropolitan areas and significant parts of rural and regional Australia. Across Australia, the I-MED Network operates over 200 medical imaging clinics. Annually, over 4 million patient examinations are performed by our 300 specialist radiologists, 50 nuclear physicians, and 3,900 staff making us one of the largest providers of medical imaging in the world. The I-MED Radiology Network was formed in July 2000, and in October 2004 merged its medical imaging business with MIA Group Limited creating Australia's largest medical imaging network. Today, the I-MED Radiology Network is a privately owned company.

Merus B.V. is a clinical-stage biomedical company focused on the discovery and development of antibody-based biopharmaceuticals, specifically in the field of immuno-oncology. The company utilizes its proprietary Oligoclonics technology to produce a class of human antibodies, which allows for the creation of a mixture of therapeutic antibodies targeting a common antigen from a single cell clone. Additionally, Merus develops bispecific antibody therapeutics known as Biclonics, which are designed to engage multiple targets simultaneously. The company's pipeline includes several product candidates such as MCLA-128, MCLA-117, and MCLA-158, among others, all aimed at addressing various cancer indications.

Terveystalo is a prominent healthcare service provider based in Finland, specializing in a comprehensive range of medical services. The company caters to corporate, private, and public sector clients, offering primary and specialized healthcare, including general practice, specialist medical care, diagnostic services, outpatient surgery, and dental care. Terveystalo's integrated approach encompasses the entire healthcare treatment chain, ensuring a seamless experience for patients. Additionally, the company operates through three reporting segments: Healthcare Services, Portfolio Businesses, and Sweden, with the majority of its revenue stemming from its Healthcare Services segment. Terveystalo is committed to delivering quality healthcare solutions tailored to the needs of diverse customer groups.

Kiadis Pharma N.V. is a biopharmaceutical company based in Amsterdam, the Netherlands, specializing in cell-based immunotherapy products aimed at treating blood cancers and inherited blood disorders. The company is currently advancing K-NK002, which is undergoing Phase II clinical trials for blood cancer patients receiving haploidentical hematopoietic stem cell transplants with the post-transplant cyclophosphamide protocol. Additionally, Kiadis Pharma is developing K-NK003, currently in Phase I/II trials for patients with acute myeloid leukemia relapse or refractory cases. The preclinical product pipeline includes K-NK00X, a natural killer (NK) cell therapy candidate targeting various solid tumors. Kiadis Pharma also collaborates with several institutions, including Harbour BioMed and Erasmus Medical Center, to explore a combination of monoclonal antibodies and natural killer cells as a potential treatment for COVID-19. Founded in 1997, Kiadis Pharma is committed to addressing significant unmet medical needs in the treatment of blood-related conditions.

IlluminOss Medical, Inc. is a commercial-stage medical device company that specializes in minimally invasive technology for fracture repair and stabilization. The company has developed a unique system that uses a light-curable polymer within an expandable balloon to create a patient-conforming intramedullary implant, facilitating effective bone stabilization. This innovative approach is particularly beneficial for patients with osteoporotic or compromised bone, providing a tailored solution for orthopedic challenges. The IlluminOss system is CE-marked and FDA-cleared for various anatomical sites, with additional indications under review. By focusing on the design and marketing of orthopedic fracture repair products, IlluminOss aims to offer clinicians a rapid and customized method for stabilizing bone fractures.

Prosensa is a biotech company also known as Ribpharm Inc dedicated to the commercialization of products for the healthcare market based on RNA-based therapeutics. During the development of this technology, it became clear that many opportunities exist for the development of these products into novel commercially attractive products. These products are mainly in the field of genetic disorders, anti-infectives and oncology. Prosensa will focus to maximize the commercial development of the current program, and take advantage of the large novel market opportunities supported by a strong IP position. Prosensa will initially operate mainly as a focussed company, outsourcing most of its activities to specialized organizations.

Pronota NV is a Belgian company specializing in the development and commercialization of innovative diagnostics aimed at the early detection of life-threatening conditions, such as heart failure, pre-eclampsia, and sepsis. The company utilizes a proprietary protein biomarker diagnostics platform that is non-invasive and validated, focusing on enhancing patient care and addressing unmet medical needs. Founded in 2004 and based in Zwijnaarde, Belgium, Pronota has garnered support from prominent investors and a network of key opinion leaders in the medical field. The firm was previously known as Peakadilly NV before rebranding in 2006.

Sapiens Steering Brain Stimulation GmbH is an emerging medical device company whose mission is to deliver superior solutions for deep brain stimulation (DBS) therapy. Sapiens' ambition is to provide a unique, high-resolution, and MRI- compatible DBS system that will improve patient comfort and therapeutic outcome, initially for patients with Parkinson's disease. Sapiens, with offices in Eindhoven, the Netherlands and Munich, Germany, is founded in 2011 as a spin-out of Royal Philips Electronics. Its steering brain stimulation (SBS) system and image-guided programming are based upon patented technologies.

Nexstim Plc is a medical technology company based in Helsinki, Finland, specializing in non-invasive brain stimulation technologies. Founded in 2000, it focuses on developing and marketing navigated transcranial magnetic stimulation (nTMS) systems, utilizing its proprietary SmartFocus technology with 3D navigation for precise targeting of brain regions. The company offers the NBT system for treating major depressive disorder and chronic neuropathic pain, as well as the NBS system for pre-surgical mapping of speech and motor cortices. Nexstim primarily serves universities and teaching hospitals, with a significant portion of its revenue generated in North America and its products marketed across Europe and internationally.

Seahorse Bioscience provides analytical instruments, biomanufacturing systems and consumable labware products for biological research and drug discovery. The company's customers include scientists at academic institutions, pharmaceutical and biotech organizations, as well as OEM manufacturers of assay kits and lab instruments suppliers.

Promethera® Biosciences is a biopharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology. Promethera® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells from healthy human livers. Promethera® Biosciences develops two products based on a newly discovered and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC):

Kreatech Diagnostics is a molecular diagnostics company that specializes in the development and commercialization of innovative detection products for diagnostic and research purposes within the life sciences and healthcare sectors. The company offers a range of Fluorescent in Situ Hybridization (FISH) probes and has established a portfolio for microarray labeling applications. Kreatech utilizes its proprietary non-enzymatic Universal Linkage System labeling technology to enhance the effectiveness of its products, contributing to advancements in molecular diagnostics.

Merus B.V. is a clinical-stage biomedical company focused on the discovery and development of antibody-based biopharmaceuticals, specifically in the field of immuno-oncology. The company utilizes its proprietary Oligoclonics technology to produce a class of human antibodies, which allows for the creation of a mixture of therapeutic antibodies targeting a common antigen from a single cell clone. Additionally, Merus develops bispecific antibody therapeutics known as Biclonics, which are designed to engage multiple targets simultaneously. The company's pipeline includes several product candidates such as MCLA-128, MCLA-117, and MCLA-158, among others, all aimed at addressing various cancer indications.

Cellerix, S.A., a biotechnology company, engages in the development and production of medicines based on the use of stem cells of adult origin. The company offers products for the treatment of gastroenterology, dermatology, and immune-based diseases. Its products include Cx401, which is used for the treatment of complex perianal fistulas; and Cx501, a cell therapy product to be applied in the treatment of Epidermolysis Bullosa. Cellerix, S.A. was founded in 2004 and is based in Tres Cantos, Spain.

Kreatech Diagnostics is a molecular diagnostics company that specializes in the development and commercialization of innovative detection products for diagnostic and research purposes within the life sciences and healthcare sectors. The company offers a range of Fluorescent in Situ Hybridization (FISH) probes and has established a portfolio for microarray labeling applications. Kreatech utilizes its proprietary non-enzymatic Universal Linkage System labeling technology to enhance the effectiveness of its products, contributing to advancements in molecular diagnostics.

Cellerix, S.A., a biotechnology company, engages in the development and production of medicines based on the use of stem cells of adult origin. The company offers products for the treatment of gastroenterology, dermatology, and immune-based diseases. Its products include Cx401, which is used for the treatment of complex perianal fistulas; and Cx501, a cell therapy product to be applied in the treatment of Epidermolysis Bullosa. Cellerix, S.A. was founded in 2004 and is based in Tres Cantos, Spain.

Pronota NV is a Belgian company specializing in the development and commercialization of innovative diagnostics aimed at the early detection of life-threatening conditions, such as heart failure, pre-eclampsia, and sepsis. The company utilizes a proprietary protein biomarker diagnostics platform that is non-invasive and validated, focusing on enhancing patient care and addressing unmet medical needs. Founded in 2004 and based in Zwijnaarde, Belgium, Pronota has garnered support from prominent investors and a network of key opinion leaders in the medical field. The firm was previously known as Peakadilly NV before rebranding in 2006.

Vivendy Therapeutics Ltd. has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity - enhancing the efficacy of the therapy in MPS IVA significantly

Nexstim Plc is a medical technology company based in Helsinki, Finland, specializing in non-invasive brain stimulation technologies. Founded in 2000, it focuses on developing and marketing navigated transcranial magnetic stimulation (nTMS) systems, utilizing its proprietary SmartFocus technology with 3D navigation for precise targeting of brain regions. The company offers the NBT system for treating major depressive disorder and chronic neuropathic pain, as well as the NBS system for pre-surgical mapping of speech and motor cortices. Nexstim primarily serves universities and teaching hospitals, with a significant portion of its revenue generated in North America and its products marketed across Europe and internationally.

Cellerix, S.A., a biotechnology company, engages in the development and production of medicines based on the use of stem cells of adult origin. The company offers products for the treatment of gastroenterology, dermatology, and immune-based diseases. Its products include Cx401, which is used for the treatment of complex perianal fistulas; and Cx501, a cell therapy product to be applied in the treatment of Epidermolysis Bullosa. Cellerix, S.A. was founded in 2004 and is based in Tres Cantos, Spain.

FlowCardia, Inc. is a medical device company established in 2002, specializing in the design and development of catheter-based technologies aimed at overcoming chronic total occlusions (CTOs) in coronary and peripheral arteries. CTOs present significant challenges in interventional therapy, often resulting in patients being referred for more invasive procedures such as bypass surgery or limb amputation due to the lack of effective recanalization devices. FlowCardia's innovative solutions seek to address this critical gap in treatment options, enhancing the safety and efficacy of procedures for patients with these difficult-to-treat conditions.

ISTO Technologies, Inc., an orthobiologics company, develops biologic products to regenerate and restore function to damaged cartilage and bone. It offers InQu, a resorbable bone graft extender and substitute; NuQu, a cell-based injectable therapy for disc regeneration; and DeNovo ET, an engineered cartilage implant for the repair and regeneration of knee cartilage. The company provides its products through distributors. ISTO Technologies, Inc. was founded in 1997 and is based in St. Louis, Missouri.

Kiadis Pharma N.V. is a biopharmaceutical company based in Amsterdam, the Netherlands, specializing in cell-based immunotherapy products aimed at treating blood cancers and inherited blood disorders. The company is currently advancing K-NK002, which is undergoing Phase II clinical trials for blood cancer patients receiving haploidentical hematopoietic stem cell transplants with the post-transplant cyclophosphamide protocol. Additionally, Kiadis Pharma is developing K-NK003, currently in Phase I/II trials for patients with acute myeloid leukemia relapse or refractory cases. The preclinical product pipeline includes K-NK00X, a natural killer (NK) cell therapy candidate targeting various solid tumors. Kiadis Pharma also collaborates with several institutions, including Harbour BioMed and Erasmus Medical Center, to explore a combination of monoclonal antibodies and natural killer cells as a potential treatment for COVID-19. Founded in 1997, Kiadis Pharma is committed to addressing significant unmet medical needs in the treatment of blood-related conditions.

PSM International is a global leader in the design, production, and distribution of engineered fastening systems, established in 1931. The company operates in 23 countries, providing a wide range of products, including nuts, studs, feed systems, ball studs, and weld nuts, tailored for various industries such as automotive, telecommunications, electronics, home appliances, medical, and energy. PSM International serves well-known brands, delivering exceptional local technical support, application engineering, project management, and customer service, all adhering to the company's high standards. Their extensive manufacturing and distribution capabilities enable them to meet the diverse needs of clients wherever manufactured goods are produced.

Affimed NV is a clinical-stage biopharmaceutical company focused on developing targeted cancer immunotherapies. With nearly two decades of expertise in the innate immune system, Affimed aims to provide innovative solutions to enhance cancer treatment outcomes. The company is engaged in the discovery, pre-clinical, and clinical development of antibodies that leverage innate cell engager-based medicines, addressing the limitations of existing immuno-oncology therapies. In addition to its product development efforts, Affimed also generates revenue by offering research and development services to third parties, utilizing both its own and third-party intellectual property.

Okairos AG, a bio-pharmaceutical company, focuses on the discovery and development of genetic T-cell vaccines, including hepatitis C virus. The company also provides health and allied services. It has operations in Rome and Naples, Italy. The company is based in Basel, Switzerland. Okairos AG was former subsidiary of Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa.

Prosensa is a biotech company also known as Ribpharm Inc dedicated to the commercialization of products for the healthcare market based on RNA-based therapeutics. During the development of this technology, it became clear that many opportunities exist for the development of these products into novel commercially attractive products. These products are mainly in the field of genetic disorders, anti-infectives and oncology. Prosensa will focus to maximize the commercial development of the current program, and take advantage of the large novel market opportunities supported by a strong IP position. Prosensa will initially operate mainly as a focussed company, outsourcing most of its activities to specialized organizations.

Movetis NV, a pharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of diseases in the gastrointestinal (GI) area. Its products address GI disorders, such as severe chronic constipation, ascites, paediatric reflux, as well as severe forms of GI motility disorders, including refractory gastro-oesophageal reflux disease. The company's lead product, Resolor, is used for the symptomatic treatment of chronic constipation in women. Resolor is also tested for chronic constipation in males and children, as well as opioid-induced constipation and post operative ileus. Its products also include M0002, which is in Phase II trials to treat ascites, an accumulation of fluid caused by liver malfunction; and M0003 that is entering Phase II development for symptomatic treatment of heartburn and regurgitation in patient's refractory to PPIs, and pediatric reflux. In addition, the company also has two prioritized compounds out of its preclinical portfolio, M0014 and M0012, and two compound libraries. It has partnership agreements with the universities of Ghent, Leuven, and Rotterdam. The company was founded in 2006 and is headquartered in Turnhout, Belgium.

Pronota NV is a Belgian company specializing in the development and commercialization of innovative diagnostics aimed at the early detection of life-threatening conditions, such as heart failure, pre-eclampsia, and sepsis. The company utilizes a proprietary protein biomarker diagnostics platform that is non-invasive and validated, focusing on enhancing patient care and addressing unmet medical needs. Founded in 2004 and based in Zwijnaarde, Belgium, Pronota has garnered support from prominent investors and a network of key opinion leaders in the medical field. The firm was previously known as Peakadilly NV before rebranding in 2006.